Lithium Therapy Guidelines

Monitoring and Safety

The American Academy of Sleep Medicine recommends monitoring serum levels twice weekly during the acute phase until both serum concentration and clinical condition stabilize, with blood samples drawn 8-12 hours after the previous dose 1
Regular monitoring of clinical state, renal function, and electrolytes is mandatory, with testing intervals of at least every 2 months for uncomplicated cases in remission, and more frequently for patients with higher risk of exceeding 1.0 mEq/L 4, 2
The Kidney International guidelines suggest temporarily discontinuing lithium in patients with GFR <30 ml/min/1.73 m² during serious intercurrent illness that increases acute kidney injury risk 4, 2
The American Academy of Sleep Medicine recommends avoiding NSAIDs as they decrease lithium clearance and increase toxicity risk, and having access to prompt and accurate serum lithium determination before initiating therapy 1, 2

Lower therapeutic levels (0.2-0.6 mEq/L) may be adequate when lithium is used to augment antidepressants, according to Praxis Medical Insights 2
Lithium toxicity is closely related to serum concentrations and can occur at doses close to therapeutic levels, with a lower limit of risk for lithium intoxication at serum levels ≥1.5 mEq/L 1, 3